概括
通过将其与FGFR1抑制相结合,可以提高对KRAS突变肺癌的治疗效果. 这种组合克服了由纤维细胞生长因子受体1 (FGFR1) 信号介导的适应性抵抗.
科学领域:
- 癌症学
- 分子生物学
- 药物发现
背景情况:
- 在癌症治疗中,KRAS突变肺腺癌是一个重大挑战.
- 直接抑制KRAS是很困难的,并且针对其效应器往往会通过补偿途径导致耐药性.
研究的目的:
- 确定一个MEK抑制剂的组合点,以克服KRAS突变肺癌的耐药性.
- 调查特拉美替尼治疗激活的补偿机制.
主要方法:
- 使用短毛针RNA查识别抗药性途径.
- 研究了纤维细胞生长因子受体1 (FGFR1) 在特拉美丁尼布耐药性的作用.
- 在试验室和体内模型中评估了与FGFR1抑制相结合的特拉梅丁尼的疗效.
主要成果:
- 治疗Trametinib诱导了补偿性FGFR1反应,导致反弹信号和适应性抵抗.
- 联合抑制FGFR1和特拉美丁尼可显著增强瘤细胞死亡.
- 在KRAS突变的肺癌和胰腺癌中,FGFR1介导的耐药性是特有的.
结论:
- 在KRAS突变肺癌中,FGFR1在调节对特拉美丁尼的适应性耐药性方面发挥着至关重要的作用.
- 与FGFR1抑制剂结合使用特拉美丁尼布,对这一患者群体是一种有前途的治疗策略.
相关概念视频
Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
The Ras Gene
7.5K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
7.5K


